We concluded that introduction of transgenic CD8α receptor in combination with Vγ5Vδ1TCR derived from clone FE11 allowed reprogramming of CD4+ T cells towards HLA-A*24:02-expressing tumor cells in vitro, though activity was lower when compared to CD8+ TEG011. This evidence concerns the gene CD4 and neoplasm.